Short Title:
Responsible HRP Element:
Human Health Countermeasures
Funding Status:
Planned - Task expected to be within budget
|
Procurement Mechanism(s):
|
| NASA Research Announcement |
|
Aims:
Determine if emerging drug (tbd) can prevent skeletal deconditioning as
characterized by bone measures (bone mass and bone turnover markers) in
bed rest subjects.
Integration/Unique Aspects:
Validate use of emerging drug (tbd) in bed rest with goal of eventual use in flight.
Ground Analog Resources
| Platform
|
Bedrest
|
| Number of Subjects
|
12
|
| Can data from subjects be collected over multiple missions/campaigns?
|
Yes
|
| Fiscal Year
|
15
|
| Days per subject
|
90
|
|
Top Level Requirements:
QCT and DXA, bone turnover markers, hormones
|
Category:
Countermeasures
Subcategory:
Prototype Hardware, Pharmaceutical, Nutritional Supplement
Description:
Demonstrate whether emerging drug (tbd) will prevent skeletal deconditioning with disuse as an analogue for spaceflight.
Customer:
HHC
Is there a signed Customer-Supplier Agreement?
No
Delivery Milestone:
9/29/2017